I think it’s very important to keep in mind that progress on our clinical pipeline remains the critical determinant in our company’s value-creation strategy. Rest assured that we are very focused on this activity accordingly.
Importantly, with three RNAi therapeutic programs in clinical development, we continue to be at the forefront of RNAi R&D, indeed we are positioned today more than ever to deliver on this technology’s enormous promise with important human data emerging in the months to come. Notable during the quarter was the initiation of our Phase I study of ALN-TTR01 for the treatment of Transthyretin -mediated amyloidosis or ATTR, our company’s third clinical program.
In addition, we continue to enroll patients in our Phase I study for ALN-VSP for liver cancer and our Phase IIb study for ALN-RSV01 in RSV-infected lung transplantations. We also have a product opt-in right on Tekmira’s PLK-1 program which is in Phase I clinical development in cancer, so we eagerly await progress and success in their efforts. Moreover, we expect to have two or more additional programs in clinical development in the next year which includes our PCSK9 program, our second-generation TTR program, and our anti-miR-122 program for the treatment of HCV infection being advanced with Regulus in collaboration with GlaxoSmithKline.
In short, it’s all about the pipeline and human data. We’re very focused on this overall clinical objective with appropriate urgency and enormous passion.I’d like to close my introductory remarks on the organization front. In this regard we were very excited to strengthen our management team this past quarter with the promotion of Ken Koblan to Chief Scientific Officer and the appointments of Steve Bossone as Vice President of Intellectual Property and Garvin Warner as Vice President of Preclinical Development. Ken Koblan is an outstanding choice as the company’s CSO. As a reminder, he joined our research group earlier this year from Merck where he played a major leadership role in their drug discovery efforts over an 18-year tenure. Steve Bossone joins Alnylam from Shire and Garvin Warner joins Alnylam from Pfizer. In addition, we also expanded our board of directors with the election of Steve Paul who is the former President of Lilly Research Laboratories of Eli Lilly & Company. Read the rest of this transcript for free on seekingalpha.com